Accelerate, Simplify and De-Risk with Catalent

Click here to subscribe to Fiercebiotech.com

2 years ago

Html
Text

This week's Fierce Biotech is brought to you by Catalent Pharma Solutions.
Trouble viewing? Click here.

Expertise Specific to the Needs of Innovators

Check out our new space dedicated to small and emerging pharma, with advice, strategies, and solutions designed for the specific needs of innovators. Leverage the experience gathered working with hundreds of small companies and learn how Catalent can help accelerate, simplify and de-risk the achievement of critical milestones.

Learn More

A Roadmap for Early Development to Commercial Manufacturing

Understanding and planning for phase-appropriate CMC-related activities can facilitate the transition from early development through commercialization. Learn more about CMC considerations for the transition from early-to-late development and critical areas of risk consideration for early- to late-phase transition. Read case studies describing consequences of unforeseen challenges in early to late-phase transition.

Integrated drug substance, drug product and clinical supply to speed your path to clinic

Biologic development is complex, with many challenges on the path to first-in-human studies. Catalent's OneBio integrated offering speeds the path to clinic while reducing timelines, risks and complexity. Thanks to accelerated cell line development and scale-up, our shortened timelines give you the ability to bring your biologic to patients faster than ever.

Every brand has a challenge. We have a solution.

Challenge Us

or call +1 877 891 9609 to speak with one of our experts today!

For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.

Catalent Pharma Solutions respects your privacy.

Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.

If you no longer wish to receive communications from Catalent Pharma Solutions, please opt out here.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017

Share on

Other newsletters from Fiercebiotech.com

| 11.25.24 | Cassava ends Alzheimer’s trial after ph .3 flop; Biohaven plots obesity pivot after SMA fail Fiercebiotech.com
3 hours ago
Optimizing Your Patient Support Strategy with Hub Model Innovation Fiercebiotech.com
5 hours ago
| 11.23.24 | House passes sweeping nonprofits bill; Trump taps Dr. Oz to run CMS Fiercebiotech.com
Last Saturday at 13:32

More newsletters from Fiercebiotech.com

Accelerate, Simplify and De-Risk with Catalent

Share on

Other newsletters from Fiercebiotech.com

Related newsletters